CER Daily Newsfeed

Semaglutide Bests Liraglutide in Long-Term Weight Loss

(9/20, Alicia Ault, Medscape) reports “...Researchers at the Cleveland Clinic reviewed records for 3389 adult patients with obesity who were prescribed one of the glucagon-like peptide 1 (GLP-1) medications for either T2D or obesity between 2015 and 2022. They found that patients who took either semaglutide or liraglutide for obesity were more likely to lose weight than those prescribed the medications for T2D and that semaglutide was associated with greater weight loss.” Full

High-Dose Haemodiafiltration Boosts Survival and Quality of Life

(9/20, European Medical Journal) reports “THE CONVINCE trial has recently revealed promising results for patients undergoing high-dose haemodiafiltration (HDF) over high-flux haemodialysis (HD). Led by Matthias Rose, Center for Patient Centered Outcomes Research, Charité Universitätsmedizin Berlin, Germany, this trial aimed to identify the best possible dialysis treatment by comparing high-dose HDF versus conventional high-flux HD treatment.” Full

Improvement Science And Value-Based Payment Models

(9/20, Tej Patel, Bhav Jain and Kedar Mate, Health Affairs Forefront) comments “...In this Forefront article, we consider a novel approach to building value-based payment models that emphasizes continuous revision during their implementation. Inspired by quality improvement models that have improved delivery system performance, we propose that iterative model development in payment may allow for a more flexible understanding of population-level risk, financial incentives that in turn promote better care delivery processes, and rapid iteration of delivery system activities to overcome inertia.” Full

NHC Provides Input on Patient Engagement in Medicare Drug Price Negotiations

(9/20, Allen Pinn, National Health Council Blog) comments “...The NHC urges CMS to consider a broad range of patient experience data, including both clinical and non-clinical outcomes. Patient-reported outcomes, quality of life measures, and treatment adherence should be represented throughout the negotiation process. The NHC also urges CMS to engage more with patient organizations to identify relevant and pertinent data points to inform its decisions. This will ensure the maximum fair price (MFP) highlights the true value of medications from the patient community’s perspective. The NHC also encourages establishing a feedback loop with patient organizations that will reinforce CMS’ commitment to truly patient-centered care.” Full